Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
bladder cancer
immunotherapy
outcomes research
performance status
urothelial carcinoma
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
received:
27
08
2019
revised:
07
10
2019
accepted:
27
10
2019
pubmed:
13
12
2019
medline:
10
10
2020
entrez:
13
12
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0-1) would correlate with shorter overall survival (OS) in patients receiving ICIs. In this retrospective cohort study, clinicopathologic, treatment, and outcome data were collected for patients with aUC who were treated with ICIs at 18 institutions (2013-2019). The overall response rate (ORR) and OS were compared for patients with an ECOG PS of 0 to 1 and patients with an ECOG PS ≥ 2 at ICI initiation. The association between a new ICI in the last 30 and 90 days of life (DOL) and death location was also tested. Of the 519 patients treated with ICIs, 395 and 384 were included in OS and ORR analyses, respectively, with 26% and 24% having a PS ≥ 2. OS was higher in those with a PS of 0 to 1 than those with a PS ≥ 2 who were treated in the first line (median, 15.2 vs 7.2 months; hazard ratio [HR], 0.62; P = .01) but not in subsequent lines (median, 9.8 vs 8.2 months; HR, 0.78; P = .27). ORRs were similar for patients with a PS of 0 to 1 and patients with a PS ≥ 2 in both lines. Of the 288 patients who died, 10% and 32% started ICIs in the last 30 and 90 DOL, respectively. ICI initiation in the last 30 DOL was associated with increased odds of death in a hospital (odds ratio, 2.89; P = .04). Despite comparable ORRs, ICIs may not overcome the negative prognostic role of a poor PS, particularly in the first-line setting, and the initiation of ICIs in the last 30 DOL was associated with hospital death location.
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0-1) would correlate with shorter overall survival (OS) in patients receiving ICIs.
METHODS
In this retrospective cohort study, clinicopathologic, treatment, and outcome data were collected for patients with aUC who were treated with ICIs at 18 institutions (2013-2019). The overall response rate (ORR) and OS were compared for patients with an ECOG PS of 0 to 1 and patients with an ECOG PS ≥ 2 at ICI initiation. The association between a new ICI in the last 30 and 90 days of life (DOL) and death location was also tested.
RESULTS
Of the 519 patients treated with ICIs, 395 and 384 were included in OS and ORR analyses, respectively, with 26% and 24% having a PS ≥ 2. OS was higher in those with a PS of 0 to 1 than those with a PS ≥ 2 who were treated in the first line (median, 15.2 vs 7.2 months; hazard ratio [HR], 0.62; P = .01) but not in subsequent lines (median, 9.8 vs 8.2 months; HR, 0.78; P = .27). ORRs were similar for patients with a PS of 0 to 1 and patients with a PS ≥ 2 in both lines. Of the 288 patients who died, 10% and 32% started ICIs in the last 30 and 90 DOL, respectively. ICI initiation in the last 30 DOL was associated with increased odds of death in a hospital (odds ratio, 2.89; P = .04).
CONCLUSIONS
Despite comparable ORRs, ICIs may not overcome the negative prognostic role of a poor PS, particularly in the first-line setting, and the initiation of ICIs in the last 30 DOL was associated with hospital death location.
Identifiants
pubmed: 31829450
doi: 10.1002/cncr.32645
pmc: PMC7050422
mid: NIHMS1062430
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1208-1216Subventions
Organisme : Wellcome Trust
ID : PS3416
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : T32 CA009515
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2019 American Cancer Society.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Clin Lab. 2013;59(3-4):429-33
pubmed: 23724636
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Lancet. 2017 Nov 18;390(10109):2266-2277
pubmed: 28916371
Lancet Oncol. 2013 Jul;14(8):769-76
pubmed: 23706985
Nat Rev Urol. 2018 Oct;15(10):585-587
pubmed: 30030491
Eur Urol. 2019 Jul;76(1):73-81
pubmed: 30910346
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Ann Transl Med. 2018 Jun;6(12):250
pubmed: 30069452
Target Oncol. 2018 Jun;13(3):353-361
pubmed: 29623487
Oncologist. 2019 Jun;24(6):e397-e399
pubmed: 30944183
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
Ther Clin Risk Manag. 2018 Jun 05;14:1019-1040
pubmed: 29892196
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Clin Genitourin Cancer. 2018 Aug;16(4):e961-e967
pubmed: 29706503
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
J Clin Oncol. 2003 Mar 15;21(6):1133-8
pubmed: 12637481
J Clin Oncol. 2010 Apr 10;28(11):1850-5
pubmed: 20231682
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Am J Hosp Palliat Care. 2020 Mar;37(3):179-184
pubmed: 31307205
Med Oncol. 2018 Aug 20;35(10):132
pubmed: 30128793
J Clin Oncol. 1999 Oct;17(10):3173-81
pubmed: 10506615
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
J Oncol Pract. 2014 Sep;10(5):e335-41
pubmed: 25118208
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060